Dual Inhibition and Optogenetic Regulation Targeting COX/5-LOX and TRPV1-Mediated Sensitization in the Neospinothalamic Pathway

Objective: The aim of this study is to elucidate the molecular sensitization mechanisms in the neospinothalamic pathway and to highlight that the limitations of current single-target therapies can be overcome with the novel experimental method of optogenetics. This study examines the neurophysiological dynamics, molecular basis, and novel therapeutic strategies involving optogenetics for pain perception within the neospinothalamic pathway, which is responsible for fast and localized pain transmission.Introduction: During transduction, the initial phase of the pain signal, nociceptors (A-delta and C fibers) become sensitized by arachidonic acid metabolites released following inflammation. A key role in this sensitization is played by prostaglandins and leukotrienes, which are produced by the cyclooxygenase and 5-Lipoxygenase enzymes. These molecules modulate the Transient Receptor Potential Vanilloid-1 ion channels, which respond to thermal and chemical stimuli, thereby increasing nociceptor excitability and leading to depolarization. The resulting electrical signal passes through a modulation phase in the dorsal horn of the spinal cord, culminating in perception in the thalamus and somatosensory cortex.Conclusion: It is suggested that future therapeutic strategies should focus on dual inhibitors that simultaneously target the cyclooxygenase and 5-Lipoxygenase enzymes, alongside Transient Receptor Potential Vanilloid-1 antagonists, to provide more comprehensive analgesia.